🔗 Share this article

Ministers and senior MPs have raised concerns that the United Kingdom's series of deals with the US administration are "fundamentally unstable." This stems from revelations that a recently announced deal on drug pricing, which promises zero tariffs in exchange for the NHS paying more, lacks any underlying contract beyond vague headline terms published in government press releases.

A Deal Without Detail

The deal on drug tariffs, described as a "generational" achievement, remains an "statement of intent" without detailed provisions. It has been highlighted that the public statements from the UK and US governments frame the deal in divergent terms. The British version celebrates securing "duty-free access" as a unique achievement, while the American announcement highlights the expectation for the NHS to pay 25% more for new medications.

"The danger exists that the UK government has agreed to terms to increase medicine costs in return for little more than a pledge from President Trump," commented David Henig, a trade expert. "History shows he has form for not following through on agreements."

Wider Concerns Amidst a Suspended Agreement

Worries have been heightened by Washington's recent decision to pause the high-value digital accord, which was previously described as "a huge leap forward" in the bilateral relationship. The US pointed to a insufficient movement from the UK on lowering trade barriers as the reason for the pause.

Furthermore, concessions secured for British farmers as part of an earlier tariff deal have yet to be formally approved by the US, despite a looming January deadline. "It is our belief that the US has not yet signed off the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have expressed concerns that the government's US-UK accords are unstable and unpredictable. One minister reportedly said the series of agreements as "built on sand," while another described the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, chair of the health select committee, remarked: "The only thing more surprising than the administration's tactics is the UK government's naive belief that his administration is a good faith actor. The NHS is of vital importance."

Official Reassurances and Concrete Outcomes

Officials have downplayed the possibility of the US backing out of the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, wanting clarity on imports and pricing, making it more concrete than the paused tech deal.

Officials concede that instability is inherent in dealing with the Trump administration. However, they maintain that the UK has achieved real benefits for businesses, such as reduced duties on automobiles compared to other nations. "Our achievement of 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a solid gain," one official said.

Nevertheless, issues have surfaced in carrying out the broader trade deal. Promised reciprocal agricultural allowances have not materialized, and the assurance to "eliminate duties on UK metals" has remains unmet, with tariffs staying at 25%.

Moving forward, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "constructive" meetings between UK and US officials in Washington.